BDBM572169 (rac)-4-chloro-3-ethyl-2,14-dimethyl-7-[3-(naphthalen-1-yloxy)propyl]-10,11,12,13,14,15-hexahydro-2H-pyrazolo[3′,4′:8,9][1,6]diazacycloundecino[10,11,1-hi]indole-8-carboxylic Acid::US11447504, Example 22::US11447504, Example 23::US11447504, Example 24::US11478451, Example 24

SMILES CCc1c-2c(CN(C)CCCCn3c(C(O)=O)c(CCCOc4cccc5ccccc45)c4ccc(Cl)c-2c34)nn1C

InChI Key InChIKey=SMIRFHPIIHOGEQ-UHFFFAOYSA-N

Data  13 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 13 hits for monomerid = 572169   

LigandPNGBDBM572169(US11478451, Example 24 | (rac)-4-chloro-3-ethyl-2,...)
Affinity DataIC50: 1.5nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
Go to US Patent

TargetBcl-2-like protein 1 [1-212]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572169(US11478451, Example 24 | (rac)-4-chloro-3-ethyl-2,...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-XL and the BH3 domain of Bad (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
Go to US Patent

LigandPNGBDBM572169(US11478451, Example 24 | (rac)-4-chloro-3-ethyl-2,...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
Go to US Patent

TargetBcl-2-like protein 1 [1-212]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572169(US11478451, Example 24 | (rac)-4-chloro-3-ethyl-2,...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-XL and the BH3 domain of Bad (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
Go to US Patent

LigandPNGBDBM572169(US11478451, Example 24 | (rac)-4-chloro-3-ethyl-2,...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
Go to US Patent

LigandPNGBDBM572169(US11478451, Example 24 | (rac)-4-chloro-3-ethyl-2,...)
Affinity DataIC50: 15nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
Go to US Patent

TargetBcl-2-like protein 1 [1-212]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572169(US11478451, Example 24 | (rac)-4-chloro-3-ethyl-2,...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-XL and the BH3 domain of Bad (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
Go to US Patent

LigandPNGBDBM572169(US11478451, Example 24 | (rac)-4-chloro-3-ethyl-2,...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
Go to US Patent

LigandPNGBDBM572169(US11478451, Example 24 | (rac)-4-chloro-3-ethyl-2,...)
Affinity DataIC50: 0.450nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
Go to US Patent

TargetApoptosis regulator Bcl-2 [1-211]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572169(US11478451, Example 24 | (rac)-4-chloro-3-ethyl-2,...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
Go to US Patent

TargetBcl-2-like protein 1 [1-212]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572169(US11478451, Example 24 | (rac)-4-chloro-3-ethyl-2,...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-XL and the BH3 domain of Bad (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
Go to US Patent

LigandPNGBDBM572169(US11478451, Example 24 | (rac)-4-chloro-3-ethyl-2,...)
Affinity DataIC50: 15nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
Go to US Patent

LigandPNGBDBM572169(US11478451, Example 24 | (rac)-4-chloro-3-ethyl-2,...)
Affinity DataIC50: 1.5nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
Go to US Patent